According to Acumen Research and Consulting, the global Extracorporeal Membrane Oxygenation (ECMO) Machine market is expected to grow at noteworthy CAGR around 4.2 % throughout the forecast period and reach around US$ 370 million by 2026.
Extracorporeal membrana oxygenation system is a system that supports patients with severe respiratory failure in the hearts and breaths. ECMO circuit includes cannulas, pumps, blenders and oxygenators that oxygenate the blood and remove carbon dioxide by means of the membrane oxygenator (OOD). The location of the cannula drainage and reinfusion port determines the ECMO model. If both drain and reinfuse are central veins, it is called venovenous ECMO or veno-artery ECMO. It is called venoarterial ECMO. Potential indications for ECMO are severely acute respiratory distress syndrome (ARDS), acute, hypercapnic, bridging lung transplant, primary post-lung graft dysfunction, and right ventricular failure pulmonary hypertension.
The report provides analysis of global ECMO market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.
The main market drivers are increasing incidences of chronic obstructive pulmonary disorder (COPD), heart disease, and respiratory failure. ECMO machines have main applications such as cardiopulmonary failure management and cardiogenic shock management and respiratory failure.
For patients undergoing heart or lung transplant surgery this treatment can also be suggested. In the U.S. nearly 6.0% of the mature populace was detected with COPD and was estimated to be a third leading cause of death in the country according to the American Journal of Respiratory and Critical Care Medicine.
Moreover, almost 50 to 90 percent of the COPD burden is undiagnosed according to the European Respiratory Journal. The increased demand is expected to increase product demand for effective critical care over the forecast period. The number of ECMO centers increased significantly after the incorporation of ECMO machinery in the treatment and management of the swine flu epidemic in 2009.
In addition, the demand for emergency care should be stepped up with increased consumption of tobacco and resulting lifestyle disorders. Increasing application in the treatment of respiratory disorders is making ECMO machines popular in hospital and medical systems. These machines are used in cardiac failure cases as well as in neonates and pediatrics to facilitate auxiliary oxygen support systems.
The ECMO machinery market is divided into pumps, controllers, oxygenators, cannula and accessories based on the component. Due to factors such as increased incidence of severe lung diseases and increased awareness of applications of the ECMO machine, the oxygenators segment is expected to dominate the market. In 2017, for example, around 28,600 people were diagnosed with cancer in Canada according to the Canadian Lung Association.
More than 11 million people are diagnosed with COPD every year, according to the America Lung Association. More than 3 million people in Japan were suffering from asthma in 2015, according to the World Health Organization (WHO), 7% of whom were severe and 30 percent were moderately asthmatic. In 2012, there was approximately 40.000 deaths from respiratory diseases in Europe, which, according to Eurostat statistics, was 8 percent of the total deaths that occurred in the same year.
The Extracorporeal Cardiopulmonary Re-Resuscitation (ECPR), respiratory and cardiac markets are segmented according to application. Each segment is further divided in neonate, pediatric and adult care according to the application. In 2018, the respiratory section govern the ECMO machinery market and represented over 44% of the worldwide share. The use of ECMO as artificial lungs can be credited to that and therefore play a key role in supporting pulmonary function.
According to an Extracorporeal Life Support Organization report from 2016, in addition, almost 45.035 patients worldwide are suffering from air diseases and require extracorporeal membrane oxygenation therapies. In 2018, ECMO was the adult segment with the highest share. The predicted profit growth in the forecast period is estimated. The increased prevalence of COPD and related cardiopulmonary conditions in adults can be attributed to this. ECMO systems are employed as an artificial heart treatment for rigorous cardiac conditions such as cardiac arrest or shock.
In 2016, approximately 22,140 patients worldwide suffered from cardiac conditions and needed ECMO according to a report published by the Extracorporeal Life Support Organization.
Rescue Therapy is also known as extracorporeal heart pulmonary resuscitation. It is used for the treatment of patients with cardiac arrest in and outside the hospital. In 2016, almost 6,421 individuals in the world required ECPR, according to the report published by the Extracorporeal Life Support Organization. ECMO is recommended for neonates who do not react to high-frequency ventilation as a treatment option.
The venous ECMO is mostly used because of a higher rate of survival compared to venous ECMO. Increased demand in ECMO systems is largely due to increased cases of chronic diseases such as COPD, emphysema and chronic bronchitis, as well as an increased awareness of disorders in the health sector. As in the United States. In 2014, there were over 8.7 million people with chronic bronchitis and 3.4 million people with emphysma at the National Center for Health Statistics.
The market is divided in arteriovenous, venoarterial and venovenous based on modality. These methods are used to support hemodynamics and facilitate the gas exchange of cardiac or respiratory insufficiency in the patient. The veno-arterial ECMO system provides both exchange of gas and hemodynamic support. It works largely by circulating blood from the heart and lungs of the patients to the ECMO system. On the other hand, the venovenous system offers the sole aid to exchange gas, in which the blood is circulated before the circulation in the heart.
The United States According In specific cases such as cardiogenic shock, veno-venous and veno-arterial combinations are used by the National Institute of Health (NIH). The venomark segment was the market leader in 2018 and, due to the wide range of treatments for cardiovascular collapse, is anticipated to expand to 4.9 percent over the projected period. For the treatment and management of decreased heart output and tissue hypoperfusion, Veno-arterial systems can be used, resulting in cardiogenic shock. This can trigger myocardial or chronic ischemia. It is not possible.
Due to the well-developed primary, secondary and tertiary hospitals, repayment frameworks, favorable government funding and a better understanding of ECMO systems, North America held the largest market share in 2018, making it easier to use hospitals. In the forecast period, Asia Pacific is expected to be the fastest growing regional market. The increased incidence of lung cancer in countries like China and India could be attributed to this. Every year, 781,000 patients have been diagnosed with lung cancer in China, according to the national cancer center (NCC), and it is one of the leading causes of cancer death in China.
Global ECMO Market, By Component
Global ECMO Market, By Modality
Global ECMO Market, By Application
Global ECMO Market, By Geography
The market research study on “Extracorporeal Membrane Oxygenation (ECMO) Machine Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global ECMO market segments with market dynamics and their impact. The report also covers basic technology development policies.
The report provides an analysis of the latest industry trends from 2015 to 2026 in all sub-segment segments and forecasts revenue and volume growth on the global, the regional and country levels.
Key Players & Strategies
Key Players include MAQUET Holding B. V. & Co. KG, Medos Mdizintechnik, Terumo Cardiovascular Systems Corporation, Nipro Medical Corporation, Microport Scientific Corporation, Sorin Group, and Medtronic, Plc. The key strategies taken by most of these companies are new product development and technological advances in the existing portfolio.
Terumo Cardiovascular Systems Corporation has made refinements in existing technology while manufacturing CAPIOX FX Oxygenator. In addition, Medtronic Plc designed Minimax Plus Oxygen System with functions such as venous aerosols and low arterial ports, integrated into the system to enhance security and performance for patients (neonates and children).